Microcurrent Neurofeedback as an Adjunct to Standard Care for Substance Use Disorders

Substance use disorder (SUD) affects millions of adults in the United States, and manypeople who receive treatment continue to struggle with cravings and co‐occurring symptomsof depression, anxiety, and post‐traumatic stress disorder (PTSD), even in intensiveresidential treatment programs. Standard residential treatment typically includesmedication (when appropriate), individual and group therapy, and peer support, butcraving often persists despite these approaches, leaving room to explore additionaltreatments that might help.Microcurrent Neurofeedback (MCN) is a non‐invasive technology that uses a person's ownbrainwave activity (EEG) to guide very low‐intensity electrical stimulation deliveredthrough sensors placed on the scalp. The goal is to help normalize patterns of brainactivity that may be involved in craving and emotional distress. MCN has shown earlypromise in small studies for depression, anxiety, and PTSD in general (non‐substance‐use)populations, but before this study, no randomized trial had tested MCN specifically inadults being treated for substance use disorder.This study was conducted as a pilot and feasibility trial, meaning its main purpose wasto generate early evidence and test whether this type of study could be carried outsuccessfully in a residential treatment setting, rather than to provide a definitiveanswer about how well MCN works. Feasibility outcomes (such as how many people could beenrolled, how many completed the study, and whether the MCN sessions could be deliveredas planned) were considered just as important as the clinical outcomes.Adults enrolled in residential substance use treatment at a partner treatment facilitywere invited to participate after completing a required 4‐week stabilization period inthe program. Eligible participants were randomly assigned, similar to a coin flip, to oneof two groups: Standard Care plus MCN, or Standard Care alone. Random assignment helpsensure the two groups are similar at the start of the study, so that any differences seenlater are more likely due to the treatment itself rather than pre‐existing differencesbetween participants.Participants assigned to receive MCN attended 12 sessions over 12 weeks, each lasting 30to 45 minutes, delivered by trained staff in a private room at the treatment facility.Because of the nature of the treatment, participants and staff could not be blinded towhich group a person was in (this is known as an open‐label design). All participants,regardless of group, continued to receive their regular Standard Care throughout thestudy.All participants completed questionnaires about substance cravings, depression, anxiety,and PTSD symptoms at three points during the study: at the start (Baseline), at themidpoint (around 6 weeks), and at the end (around 12 weeks). These questionnaires arewidely used, validated tools in mental health and addiction research. Becauseparticipants were enrolled in a residential treatment program, some left the programbefore completing the study, which is a known challenge in this type of research; thestudy's analysis approach was designed to account for this as much as possible.A subset of participants also had their brain activity recorded using EEG, and a smallersubset underwent MRI brain scans, to explore whether measurable changes in brain activityor structure accompanied any changes in symptoms. These neuroimaging findings are beinganalyzed and reported separately from the main clinical results.This study did not directly measure drug or alcohol use, relapse, or abstinence; itfocused specifically on craving and psychiatric symptoms. Findings from this pilot studyare intended to inform the design of a larger, more definitive future trial.